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We present a sibling pair with Leigh-like disease, progressive hypotonia,
regression, and chronic encephalopathy. Whole exome sequencing
in the younger sibling demonstrated a homozygous thiamine
pyrophosphokinase (TPK) mutation. Initiation of high dose thia-
mine, niacin, biotin, α-lipoic acid and ketogenic diet in this child
demonstrated improvement in neurologic function and re-attainment of
previously lost milestones. The diagnosis of TPK deficiency was difficult
due to inconsistent biochemical and diagnostic parameters, rapidity of
clinical demise and would not have been made in a timely manner
without the use ofwhole exome sequencing.Molecular diagnosis allowed
for attempt at dietary modification with cofactor supplementation which
resulted in an improved clinical course.
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1. Introduction
Thiamine pyrophosphate (TPP) is a required cofactor for the mitochondrial enzyme complexes pyruvate
dehydrogenase, α-ketoacid dehydrogenase, and branched chain ketoacid dehydrogenase. It is also required for
the cytosolic transketolase and the peroxisomal α-oxidation of 3-methyl-branched and straight chain
2-hydroxy long chain fatty acids by 2-hydroxyacyl-CoA lyase 1. TPP is synthesized by the enzyme thiamine
pyrophosphokinase (TPK) [1–17].Mayr et al. demonstrated that patientswith autosomal recessivemutations in
TPK can present with variable degrees of encephalopathy, developmental delay and hypotonia [18]. In their
cohort, illness and other causes of increased catabolism triggered acute decompensation. The individuals with
TPKmutations hadmotor dysfunction particularly related to striatal, basal ganglial, and cerebellar regions of the
brain, but cognition appeared to remain intact [18]. In the three families previously reported, the range of
symptomatic presentation was between 18 months and 4 years. Thiamine supplementation was attempted in
three out of five patients. Two of those were reported to have stabilization of symptoms with some
improvement in function. One childwas placed on a 70% fat containing diet. Laboratory analyses obtained in this
cohort noted consistent elevations in α-ketoglutaric acid [18].
2. Case series
Herewe describe the clinical presentation and care of a sibling pair, born to consanguineous second-cousins
of Chinese descent.
2.1. Patient 1
P1 was born via cesarean section for fetal decelerations at term. Initial developmental delay and hypotonia
were noted at 7 months of age with slow developmental progress until 26 months, when she developed a
febrile illness and rapidly regressed in both motor and cognitive milestones. At 28 months of age she was
admitted to hospital for increasing fatigue, weakness, decreased oral intake, lethargy, and intractable seizures
with severe and rapid progression to coma. She died at 29 months secondary tomulti-organ failure after having
suffered multiple metabolic strokes in the setting of metabolic collapse.
Cerebral MRI at 12 months of age demonstrated T2 bright abnormalities (Fig. 1, A–C) in the basal
ganglia and thalami. Repeat MRI during her metabolic collapse at 28 months revealed progressive findings
suggestive of mitochondrial disease (Fig. 1, D–F).
Pre- and post-mortem laboratory evaluations were extensive. Cytogenetic, molecular and biochemical
analyses included karyotype, mitochondrial DNAmutation and deletion analysis, plasma amino acids, electron
transfer analysis viamuscle biopsy, pyruvate carboxylase and pyruvate dehydrogenase levels frompostmortem
fibroblast analyses. All the studies were non-diagnostic. Urine organic acids demonstrated elevations in lactic,
α-ketoglutaric and fumaric acids. Thiamine levels were not obtained during her clinical decompensation or
post-mortem studies.
2.2. Patient 2
P2 was born at 38 weeks of gestation via repeat cesarean section after an uneventful pregnancy. Initial
evaluation at two weeks was without concern as he was breast-feeding well, with normal tone and
neurologic exam. By four months, his exam demonstrated mild hypotonia, episodic extremity stiffening
and a decreased level of alertness.
By 12 months of age, his hypotonia progressed with inconsistent head control, inability to sit without
support, and persistent drooling with poor oral intake. A cranial MRI with sedation was obtained at this
time and revealed T2 abnormalities similar to his sibling (Fig. 1, G–I). At 18 months he was admitted to the
hospital because neurological decline. His exam was notable for complete loss of head control, bulbar
dysfunction, fatigue, weakness, worsening hypotonia, and persistent food refusal except for very small
quantities of a traditional Chinese rice porridge. Immediately upon admission, additional biochemical
laboratory evaluation was performed, and aggressive management of his fluid and nutritional status was
initiated because of his sister's rapid metabolic decompensation prior to her death. Laboratory analyses
included interpretations of plasma amino acids, acylcarnitine profile, lactate, pyruvate and very long chain
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fatty acids, which were all non-diagnostic. As in P1, urine organic acids demonstrated elevations of
α-ketoglutarate and glutaric acids. Mild lactic acidosis was present but easily resolved with rehydration.
Due to the history of consanguinity and similar clinical presentation as his sibling, whole exome
sequencing (WES) was pursued. Results were available concurrent to the 18 month admission, and a
diagnosis of thiamine pyrophosphokinase (TPK) deficiency was made. TPP levels were not available due to
insurance regulations prior to or following admission. As the sibling's muscle biopsy was not diagnostic,
consideration for additional muscle and skin biopsies were felt to be of marked risk and were not pursued
due to the history of neurologic decline with anesthesia after the cranial MRI. Medical therapy was
initiated.
2.3. Molecular diagnosis
Whole exome sequencing (WES) performed in a CLIA-approved laboratory revealed a homozygous
missense mutation in TPK (*606370) (c.604 TNG; p.W202G). This mutation is located in the thiamine
binding domain, in a moderately conserved nucleotide and highly conserved amino acid, and is predicted
to be pathogenic by in-silico analyses using PolyPhen, SIFT, and Alamut. Both parents are heterozygous for
the mutation. Confirmatory testing on residual post mortem DNA from P1 revealed that she was also
homozygous for the same mutation.
2.4. Therapeutic strategy
Because of his neurologic regression and the severity of his sister's presentation, P2 was treated with a
generalized and aggressive approach of both diet modification and cofactor supplementation. The working
hypothesis was that TPK1 deficiency possibly affected the TCA cycle. Supplementation included thiamine
(10 mg/kg, 3 times per day) with the assumption there was some residual TPK enzyme activity.
Additionally, niacin (10 mg/kg, 3 times per day), biotin (5 mg, 3 times per day), and α-lipoic acid (5 mg/kg,
3 times per day) were initiated to provide further cofactor support for other presumably affected
metabolic pathways. Ketogenic diet (Ketocal 3:1) via nasogastric tube feeding was initiated to reduce
metabolic demand through pyruvate dehydrogenase (PDH). The premise of this therapy was to factor in
the consumption of TPP required for normal function of PDH in a standard, carbohydrate-prominent diet.
After almost nine months on this diet modification, both the cofactor supplements and ketogenic diet
continue to be well tolerated and the family is extremely hesitant to change any medical intervention at
this time.
2.5. Clinical progress following therapeutic intervention
Since initiation of therapy, P2, now 29 months old, has demonstrated markedly improved head control,
stability of truncal tone, increased verbal response and social interaction. He is not able to walk, but is able
to stand with support. Though most of the diet is provided via a nasogastric tube, he is now able to
supplement with oral intake in small quantities, point to his body parts, and maintain a sitting position.
During a recent viral illness, oral intake decreased and bulbar signs (drooling and lethargy) were
transiently present, but did not persist after resolution of the illness. Administration of live virus vaccines
(measles, mumps, and rubella (MMR) and varicella) had been postponed due to concerns over possible
concurrent decompensation. He tolerated vaccination with killed, acellular vaccines (including influenza)
during a controlled hospitalization with intravenous hydration. Analysis of urine organic acids revealed
lactate, ketone and TCA cycle moieties which were identical just prior to and 24 h after vaccine
administration. In comparison, the levels of these moieties were also similar to those obtained when he
was clinically well.
3. Discussion
Currently, whole exome sequencing remains the only clinically available molecular testing modality for
TPK deficiency. Based upon the experiences with this family, the diagnosis is likely under-recognized as a
cause of Leigh-like encephalopathy. These siblings are the youngest reported with TPK deficiency and have
68 J.L. Fraser et al. / Molecular Genetics and Metabolism Reports 1 (2014) 66–70
the most severe presentation with rapid and progressive neurologic decline. Biochemical analysis of TPP
quantitation and TPP: total thiamine ratios could be utilized to suggest an underlying deficiency but are
not clinically available in this country, and may not allow for a diagnosis in time for clinical management.
While biochemical testing in this family and the cohort of Mayr et al. revealed an elevation of
α-ketoglutarate in the urine, P2's serial analyses of urine organic acids and α-ketoglutarate during the
initiation of diet, febrile illness, and vaccine administration were not correlative to his clinical examination
and could not be used to monitor medical management.
The molecular diagnosis in this family helped to provide a definitive diagnosis in a time frame that
allowed for an attempt at dietary intervention. It was also directive for appropriate genetic counseling of
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affected and carrier family members. This is the first report of use of dietary management in the setting of
cofactor supplementation to improve a clinical outcome in a patient with severe TPK mutations. These
experiences suggest that patients with elevation of urinary α-ketoglutarate and phenotypic similarity to
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Fig. 1. MRI findings in sibling pair with TPK deficiency. A–C, MRI of Patient 1 at 11 months of age. Axial FLAIR (A), proton density
(B) and T2 (C) images at the level of the thalamus. The images demonstrate increased signals in the posterior aspect of the putamen
bilaterally (large arrowheads), and subtle changes in the ventrolateral thalamus (small arrowhead, C). Myelination was normal for
age. D–F, MRI of Patient 1 at 28 months. Axial FLAIR images at the level of the lower pons (D), the midbrain (E), and the thalami
(F). Increasing T2 signal abnormalities have developed, involving bilateral caudate, putamen, globus pallidus, thalami and optic
radiations (arrowhead, F). The corticospinal tracts traveling through the midbrain, pons and medulla are involved (arrowheads,
D and E), with additional abnormal signals in the posterior pontine tracks and deep cerebellum (D). Restricted diffusion with signal
changes was present in the caudate, putamen and globus pallidus, as well as parts of the thalami and corticospinal tract (not
illustrated). G–I, MRI of Patient 2 at 12 months of age. Axial T2 FLAIR (G), spin echo proton density (H) and T2 (I) images. The extent
of myelination is advanced for age. Abnormal hyperintense T2 signal is evident in the posterior putamina and thalami (arrowheads)
bilaterally. Abnormal signal in the dentate nuclei was present (not illustrated). MR Spectroscopy over the basal ganglia
demonstrated nonspecific increase in the choline to creatine ratio with no lactate peak, and diffusion images were normal (not
illustrated). Findings are similar in pattern and distribution to his sibling's.
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